Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Key Milestones in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market’s Growth Trajectory From 2025 To 2034?
The market for poly (adp-ribose) polymerase (parp) inhibitors has witnessed a considerable surge in recent years. There is a projected growth of the market size from $6.53 billion in 2024 to $7.49 billion in 2025, with a compound annual growth rate (CAGR) of 14.8%. The historic evolution can be credited to the climb in cancer cases, rise in genetic testing, greater success rates in clinical trials, increased insurance coverage, and progress in cancer research.
The market for poly (adp-ribose) polymerase (parp) inhibitors is anticipated to experience swift expansion in the upcoming years, expanding to a valuation of $13.15 billion in 2029, registering a compound annual growth rate (CAGR) of 15.1%. The predicted boom in this period owes its origin to an increase in the production and distribution of medications, the rising occurrence of BRCA-mutated cancers, an upward trend in breast cancer, increased utilization of monoclonal antibodies, and growing health expenditure. Predominant trends predicted for this period incorporate progress in biomarker research, combined treatment approaches, the utilization of artificial intelligence in drug creation, advancements in therapy based on biomarkers, and the evolution of next-generation PARP inhibitors.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22102&type=smp
Which Major Market Drivers Are Expected to Boost the Growth Potential of the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market?
The growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market is anticipated to be driven by the increasing incidence of breast cancer. Breast cancer is an illness characterized by uncontrolled cell growth in the breast, leading to a malignant tumor that can spread to other body parts. The escalating prevalence of breast cancer is linked to factors such as aging, lifestyle modifications, genetic predisposition, hormonal disorders, obesity, alcohol intake, and amplified exposure to environmental risks. PARP inhibitors aid in the treatment of breast cancer by inhibiting the PARP enzyme from repairing DNA damage in cancer cells, which results in cell death, particularly in tumors with BRCA1 or BRCA2 mutations. For example, the National Breast Cancer Foundation, located in the US, stated in January 2025 that one out of every eight women in the United States will be diagnosed with breast cancer in their lifetime. In 2024, cases of invasive breast cancer were reported in 310,720 women and 2,800 men. Consequently, the surge in breast cancer occurrences is promoting the expansion of the poly(ADP-ribose) polymerase (PARP) inhibitors market.
Which Key Market Segments Comprise the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market and Drive Its Revenue Growth?
The poly (adp-ribose) polymerase (parp) inhibitorsmarket covered in this report is segmented –
1) By Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Types
2) By Indication: Ovarian Cancer; Breast Cancer; Prostate Cancer; Pancreatic Cancer
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Hospitals; Specialty Clinics; Research Institutions; Other End-Users
Subsegments:
1) By Olaparib: BRCA-Mutated Cancers; HRD-Positive Cancers; Maintenance Therapy
2) By Rucaparib: Ovarian Cancer; Prostate Cancer; Pancreatic Cancer
3) By Niraparib: First-Line Treatment; Recurrent Cancer Treatment; Late-Stage Cancer
4) By Talazoparib: Breast Cancer; Germline BRCA-Mutated Tumors; Neoadjuvant Or Adjuvant Therapy
5) By Other Types: Emerging PARP Inhibitors; Investigational Therapies; Novel Combinations
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=22102&type=smp
Which Areas Are Leading Regions in the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Expansion Across the Globe?
North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Key Market Trends in thePoly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Over the Coming Years?
Key players in the poly(ADP-ribose) polymerase (PARP) inhibitors market are honing in on crafting sophisticated cancer therapies, such as anticancer drugs, specifically aimed at characteristic genetic mutations seen in certain types of cancer. Anticancer drugs are employed to manage cancer by halting the proliferation of cancer cells, preventing their spread, or ultimately eliminating them. They function through several mechanisms of action, including interrupting cell division, hindering specific proteins that are crucial for tumor growth, or activating the immune system to combat the disease. For instance, in March 2024, India-based pharmaceutical tycoon, Zydus Lifesciences Limited, unveiled IBYRA, a generic counterpart of the PARP inhibitor olaparib, in India. This medication represents an economic and pinpointed treatment choice for patients suffering from HRD-positive and BRCA-positive malignancies. It substantially trims down treatment expenses when compared to the original drug.
View the full report here:
How Is the Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Conceptually Defined?
PARP inhibitors (poly(ADP-ribose) polymerase inhibitors) are a group of drugs mainly used in cancer therapy. These medications work by blocking DNA repair in cancer cells, particularly in cancers with BRCA mutations. They are commonly used to treat ovarian and breast cancer and are usually taken orally. PARP inhibitors help reduce the risk of cancer returning after chemotherapy and can cause side effects such as fatigue and low blood cell counts.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22102
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model